Improving on Rituximab – Selecting CD20 mAb for the Future
3,287 views
|
December 23, 2011
The anti-CD20 mAb Rituximab, has transformed treatment of lymphoma. Despite this success a substantial proportion of B-cell lymphomas are refractory. Here, we present the case for focusing on so-called type II anti-CD20 mAb in the future.
Flow ChemistryUp Next
Autoplay
More Videos from SELECTBIO
